Early products of hemoglobin-based oxygen carriers (HBOCs) exposed in clinical trials the problems that free hemoglobin scavenges nitric oxide, causing vasoconstriction and elevated blood pressure and increasing the risk of myocardial infarction and stroke, and that hemoglobin is easily and rapidly cleared by the kidneys in plasma, with a short half-life.